source
- Overlooked drugs can gain value when markets evolve, says Azurity CEORon Scarboro, chief executive of Azurity Pharmaceuticals, wrote about how medicines that seemed unsuccessful can become valuable when market conditions change. He argues that the industry often co…
- BioNTech's HER2-directed ADC shows modest benefit and higher lung toxicity in phase 3 trialBioNTech reported results of its phase 3 DYNASTY-Breast02 trial evaluating trastuzumab pamirtecan (t-pam), an HER2-directed antibody-drug conjugate, in patients with HR-positive, HER2-low metastati…